ArticleScientific reports2025
Biochemical and molecular evaluation of resveratrol and selenium nanoparticles in managing type 2 diabetes and its complications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Harnessing Medicinal Plants Through Advanced Drug Delivery: A New Era in Type 2 Diabetes Management.Pharmaceutics · 2026Review
- Computational Investigation of Cinnamon Phytochemicals Targeting Key Cancer Signaling Pathways: Molecular Docking, ADMET and Molecular Dynamics Simulations Analysis.Current issues in molecular biology · 2026Article
- Selenium-loaded sustained-release schizophyllan alleviates pancreatic and pulmonary inflammatory damage in type 1 diabetes mellitus by modulating gut microbiota and T cell balance.Journal of nanobiotechnology · 2026Article
- New Perspectives on the Use of Resveratrol in the Treatment of Metabolic and Estrogen-Dependent Conditions Through Hormonal Modulation and Anti-Inflammatory Effects.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic potential of dietary polyphenols, such as resveratrol (Res) and elemental selenium nanoparticles (SeNPs), has gained increasing attention for the treatment and management of type 2 diabetes mellitus (T2DM). In this study, we investigated a novel therapeutic strategy using chitosan-stabilized Res/SeNPs (CS/Res/SeNPs) in a mouse model of T2DM induced by high-fat diet (HFD) feeding combined with multiple low-dose streptozotocin (STZ) injections. We evaluated the effects of these nanoparticles on glucose and insulin levels, oxidative/antioxidant balance, expression of apoptotic and anti-apoptotic genes, and inflammatory mediators using biochemical, histopathological, and molecular docking analyses. Treatment with free Res, CS/Res/SeNPs-5, CS/Res/SeNPs-10, and Metformin (Met) improved hyperglycemia, insulin resistance (IR), and dyslipidemia, and normalized elevated liver and kidney biomarkers. These treatments also exhibited anti-inflammatory, antioxidant, and anti-apoptotic effects. CS/Res/SeNPs-10 showed the most potent hepatoprotective and anti-diabetic effects. The docking results revealed that Res binds to key insulin signaling proteins, such as phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR). Collectively, our findings highlight the therapeutic promise of CS/Res/SeNPs in managing T2DM complications and suggest a cost-effective strategy to enhance health outcomes and quality of life in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.